% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:134725,
      author       = {Galldiks, Norbert and Rapp, Marion and Stoffels, Gabriele
                      and Dunkl, Veronika and Sabel, Michael and Langen,
                      Karl-Josef},
      title        = {{E}arlier {D}iagnosis of {P}rogressive {D}isease during
                      {B}evacizumab {T}reatment {U}sing
                      {O}-(2-18{F}-{F}luorethyl)-{L}-tyrosine {P}ositron
                      {E}mission {T}omography in {C}omparison with {M}agnetic
                      {R}esonance {I}maging.},
      journal      = {Molecular imaging},
      volume       = {12},
      number       = {5},
      issn         = {1535-3508},
      address      = {Hamilton, Ont.},
      publisher    = {Decker},
      reportid     = {FZJ-2013-02822},
      pages        = {273-276},
      year         = {2013},
      abstract     = {AbstractAntiangiogenic treatment using bevacizumab in brain
                      tumor patients may cause difficulties in the diagnosis of
                      tumor progression (ie, nonenhancing tumor progression).
                      Newly defined criteria for treatment assessment and
                      diagnosis of tumor progression (ie, RANO [Response
                      Assessment in Neuro-Oncology] criteria) have implemented
                      signal alterations on T2/fluid-attenuated inversion recovery
                      (FLAIR) sequences to changes in contrast enhancement.
                      However, T2/FLAIR hyperintensity may be influenced by other
                      causes (eg, radiation-induced leukoencephalopathy,
                      peritumoral edema, gliosis). Positron emission tomography
                      using the radiolabeled amino acid
                      O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET-PET) may help
                      detect the metabolically active tumor extent. We present
                      18F-FET-PET imaging findings in a glioblastoma patient
                      during bevacizumab treatment suggesting an earlier diagnosis
                      of tumor progression than magnetic resonance imaging
                      changes, which are based on the RANO criteria.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {332 - Imaging the Living Brain (POF2-332)},
      pid          = {G:(DE-HGF)POF2-332},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:23759368},
      UT           = {WOS:000336724400005},
      doi          = {10.2310/7290.2013.00051},
      url          = {https://juser.fz-juelich.de/record/134725},
}